Tema Etfs LLC Has $4.19 Million Stock Holdings in Boston Scientific Corporation $BSX

Tema Etfs LLC raised its stake in Boston Scientific Corporation (NYSE:BSX) by 148.1% in the 3rd quarter, HoldingsChannel reports. The firm owned 42,950 shares of the medical equipment provider’s stock after acquiring an additional 25,641 shares during the quarter. Tema Etfs LLC’s holdings in Boston Scientific were worth $4,193,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Riverwater Partners LLC grew its stake in shares of Boston Scientific by 3.3% in the 2nd quarter. Riverwater Partners LLC now owns 3,104 shares of the medical equipment provider’s stock valued at $333,000 after buying an additional 98 shares during the period. Gerber Kawasaki Wealth & Investment Management boosted its holdings in Boston Scientific by 3.8% in the second quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider’s stock worth $291,000 after acquiring an additional 99 shares in the last quarter. Crown Wealth Group LLC grew its stake in Boston Scientific by 4.7% in the third quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider’s stock valued at $218,000 after acquiring an additional 100 shares during the period. IVC Wealth Advisors LLC increased its holdings in shares of Boston Scientific by 4.9% during the second quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider’s stock valued at $236,000 after acquiring an additional 102 shares in the last quarter. Finally, Sound View Wealth Advisors Group LLC raised its position in shares of Boston Scientific by 3.9% during the second quarter. Sound View Wealth Advisors Group LLC now owns 2,738 shares of the medical equipment provider’s stock worth $294,000 after purchasing an additional 103 shares during the period. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Down 0.7%

Boston Scientific stock opened at $97.68 on Monday. Boston Scientific Corporation has a fifty-two week low of $85.98 and a fifty-two week high of $109.50. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. The firm’s 50-day simple moving average is $97.58 and its 200 day simple moving average is $100.73. The stock has a market cap of $144.80 billion, a PE ratio of 52.23, a price-to-earnings-growth ratio of 1.73 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The firm had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. During the same period last year, the firm posted $0.63 EPS. The business’s revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares in the company, valued at $17,739,678.74. This trade represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares of the company’s stock, valued at $2,396,580. The trade was a 42.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 93,095 shares of company stock worth $9,305,450. 0.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Morgan Stanley lifted their price target on shares of Boston Scientific from $125.00 to $130.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. Erste Group Bank cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday, October 3rd. Leerink Partners boosted their target price on shares of Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Boston Scientific in a research report on Wednesday, October 8th. Finally, Barclays boosted their price objective on Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a report on Thursday, October 2nd. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Boston Scientific currently has an average rating of “Buy” and an average price target of $125.21.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.